Form 4: Natera Executive Chairman Sells Shares Under 10b5-1 Plan

Natera's Executive Chairman, Matthew Rabinowitz, sold 22,900 shares of common stock on November 4, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc., reported the sale of common stock.
• A total of 22,900 shares were sold on November 4, 2025.
• 17,198 shares were sold at a weighted average price of $200.2887 per share, with prices ranging from $200.00 to $200.74.
• An additional 5,702 shares were sold at a weighted average price of $201.1766 per share, with prices ranging from $201.01 to $201.38.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 13, 2025.
• Following these transactions, Rabinowitz directly beneficially owns 2,280,852 shares and indirectly owns 5,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While it's an insider sale, the fact that it's under a 10b5-1 plan mitigates immediate negative implications, suggesting a pre-planned liquidity event rather than a reaction to new adverse information. However, any insider selling can be viewed with caution by investors.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, undisclosed negative information.
• The Executive Chairman retains a significant direct beneficial ownership of 2,280,852 shares, plus indirect ownership, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, can be perceived negatively by the market as it reduces the insider's direct equity stake in the company.
• The sale occurred at prices above $200 per share, which could be interpreted as the insider taking advantage of a strong stock performance.

Future Outlook

na

Industry Context

na

Related Party Transactions

• Matthew Rabinowitz, Executive Chairman and Director, sold shares of Natera common stock, which is a direct transaction between an insider and the market.

Stakeholder Impact

• Shareholders: May perceive the insider sale as a slight negative, potentially impacting short-term sentiment, though the 10b5-1 plan mitigates this.

Key Dates

Recommendation

The insider sale by the Executive Chairman, while significant in volume, was executed under a pre-arranged Rule 10b5-1 trading plan. This suggests a planned liquidity event rather than a reaction to new, negative company-specific news. Given the continued substantial direct and indirect ownership by the Executive Chairman, the transaction does not fundamentally alter the investment thesis for Natera. Investors should monitor future filings and company performance, but this specific transaction alone does not warrant a change from a 'hold' position.

Keywords

Natera, NTRA, Form 4, Insider Trading, Stock Sale, Matthew Rabinowitz, 10b5-1 Plan, Executive Chairman, Biotechnology, Healthcare